Chronic kidney disease is a progressive disease with no cure and high morbidity and
mortality that occurs commonly in the general adult population, especially in people with …

As a major component of cell membrane lipids, Arachidonic acid (AA), being a major
component of the cell membrane lipid content, is mainly metabolized by three kinds of …

Background B-cell anomalies play a role in the pathogenesis of membranous nephropathy.
B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine …

Background A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for
membranous nephropathy. Compared with this regimen, rituximab therapy might have a …

Membranous nephropathy is characterized by deposition of immune complexes along the
glomerular basement membrane. PLA2R and THSD7A are target antigens in 70% and 1-5 …

B cells play a central role in the immunopathogenesis of glomerulonephritides and
transplant rejection. B cells secrete antibodies that contribute to tissue injury via multiple …

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a
Controversies Conference on glomerular diseases in November 2017. The conference …

Membranous nephropathy (MN) is characterized histomorphologically by the presence of
immune deposits in the subepithelial space of the glomerular filtration barrier; its clinical …

Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by
autoantibodies against the recently discovered podocyte antigens: the M-type …

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been
conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals …